FDA
-
-
-
-
-
-
-
Jaguar Health Reports First Quarter 2026 Financials
-
-
-
-
-
-
-
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
-
-
-
-
-
-
-
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
-
-
-
-
-
-
-
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
-
-
-
-
-
-
-
Jaguar Health submits abstract for crofelemer trial in short bowel syndrome
-
-
-
-
-
-
-
Jaguar Health receives Australian patent for crofelemer in short bowel syndrome
-
-
-
-
-
-
-
Jaguar Health meets with FDA on rare disease drug development
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

